The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans

Cardiovascular Drug Reviews

Volumn 18, Issue 4, 2000, Pages 259-270

  McDowell, Garry ^a   Nicholls, D Paul ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Candoxatril; Natriuretic peptides; Neutral endopeptidase inhibitors

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDOXATRIL; CANDOXATRILAT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; FUROSEMIDE; OMAPATRILAT; PERINDOPRIL; PRODRUG; SINORPHAN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034525344     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2000.tb00051.x     Document Type: Review

References (84)

1. Thrombin mediated down regulation of endothelial receptors in mesangial cells coincides with down regulation of neutral endopeptidase activity
2. Anaritide in acute tubular necrosis
3. Clearance function of the type C receptors of atrial natriuretic factor in rats
4. Atrial natriuretic factor receptors and signal transduction mechanisms
5. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on haemodynamics, sympathetic activity, heart rate variability and endothelin
6. Urinary neutral endopeptidase 24.11 activity. Modulation by chronic salt loading
7. The atriopeptidase inhibitor (±) candoxatrilat reduces the clearance of atrial natriuretic factor in both intact and nephrectomised rats: Evidence for an extra renal site of action
8. Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension
9. Diverse biological actions of ANP
10. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats
11. Effects of physiological increments in human atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects
12. C-type natriuretic peptide: A selective cardiovascular profile
13. Chronic haemodynamic effects of candoxatril - A multicentre dose-ranging study
14. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-Centre Dose Ranging Study Investigators
15. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: Effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels
16. Atrial stretch, not pressure, is the principal determinant controlling the release of atrial natriuretic factor
17. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure
18. Role of neutral endopeptidase in control of peripheral vascular tone in man
19. 2+ effects in normal man
20. Atrial natriuretic factor clearance receptor
21. Enhanced natriuretic response to neutral endopeptidase inhibition in heart transplant recipients
22. Renal responses to candoxatrilat in patients with heart failure
23. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cell
24. Congestive heart failure: Central role of the arterial blood pressure
25. Genetic decreases in atrial natriuretic peptide and salt sensitive hypertension
26. Comparison of the acute vascular effects of frusemide and bumetanide
27. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog, man following administration of the pro-drug candoxatril
28. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure
29. Effect of ecadotril, a neutral endopeptidase inhibitor, on myocardial hypertrophy in the rat aortic insufficiency model
30. Effect of endopeptidase 24.11 inhibitors and atrial natriuretic peptide clearance receptor ligand and response to rat brain natriuretic peptide in concious rat
31. C-type natriuretic peptide (CNP) in rats and humans
32. Effect of atriopeptidase inhibitor UK-79,300 on left ventricular hydraulic load in patients with congestive heart failure
33. Effect of atriopeptidase inhibitor UK- 79300 on aortic impedance in patients with congestive heart failure
34. Suppression of atherosclerotic changes in cholesterol fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11
35. Influence of candoxatril on plasma brain natriuretic peptide in heart failure
36. Clearance of brain natriuretic peptide in patients with chronic cardiac failure: Indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism
37. Natriuretic peptides
38. Physiological role of silent receptors of atrial natriuretic factor
39. Abnormal vascular responses in human chronic cardiac failure are both endothelium-dependent and endothelium-independent
40. The role of neutral endopeptidase in dogs with evolving congestive heart failure
41. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides
42. The natriuretic peptide family
43. Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure
44. Dose ranging effect of candoxatril on elimination of exogenous atrial natriuretic peptide
45. Brain natriuretic peptide as a novel cardiac hormone in humans
46. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
47. Candoxatril improves exercise capacity in patients with chronic heart failure
48. Effects of UK 69578: A novel atriopeptidase inhibitor
49. Effects of candoxatril, a novel endopeptidase inhibitor, compared to frusemide in heart failure
50. Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: Effects on diastolic function
51. Inhibition of metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure
52. A multi-centre double-blind, placebo controlled trial comparing neutral endopeptidase inhibition with converting enzyme inhibition in chronic heart failure
53. UK 79300 and orally active atriopeptidase inhibitor raises plasma atrial natriuretic peptide and is natriuretic in essential hypertension
54. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension
55. Renal and hormonal effects of chronic inhibition of neutral endopeptidase in normal man
56. Molecular cloning of the complimentary DNA and gene that encodes mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene
57. Plasma brain natriuretic peptide and neutral endopeptidase 24.11 inhibition in hypertension
58. EC 2411 inhibition in man alters clearance of atrial natriuretic peptide
59. Inhibition of endopeptidase 24.11 in man, renal, endocrine and haemodynamic effects
60. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II
61. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin-II in human volunteers
62. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects
63. Neutral endopeptidase 24.11: Structure, inhibition and experimental and clinical pharmacology
64. Vasopeptidase inhibitor or angiotensin converting enzyme inhibitor in heart failure? Results of the IMPRESS trial
65. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake
66. Is atrial natriuretic peptide guanosine 3′5′ cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension
67. The natriuretic and diuretic efficacy of an orally active atriopeptidase inhibitor UK 79300 in mice
68. Atriopeptidase inhibitors: A novel class or drug that rises atrial natriuretic factor: The pre-clinical pharmacology
69. Inhibition of neutral endopeptidase (EC 3.4.24.11) leads to an atrial natriuretic factor mediated natriuretic, diuretic and antihypertensive response in rodents
70. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension
71. Identification of protease 3.4.24.11 as major atrial natriuretic factor degrading enzyme in rat kidney
72. Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal controls
73. Hypertension in transgenic mice expressing atrial natriuretic factor fusion genes
74. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension
75. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
76. Cardio-renal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene
77. Endopeptidase 24.11 and its inhibition: Potential therapeutic agents for edematous disorders and hypertension
78. Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia
79. Metabolic clearance rate and plasma half-life of alpha-human atrial natriuretic peptide in man
80. Atrial natriuretic factors significantly contribute to the mineralocorticoid escape phenomenon: Evidence for a guanylate cyclase mediated pathway
81. Inhibition of kidney endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: Quantitation by autoradiography
82. Hemodynamic, renal and hormonal responses to BNP in patients with congestive heart failure
83. Effect of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung